DE60315296D1 - Zell-selektives Abgabe System - Google Patents

Zell-selektives Abgabe System

Info

Publication number
DE60315296D1
DE60315296D1 DE60315296T DE60315296T DE60315296D1 DE 60315296 D1 DE60315296 D1 DE 60315296D1 DE 60315296 T DE60315296 T DE 60315296T DE 60315296 T DE60315296 T DE 60315296T DE 60315296 D1 DE60315296 D1 DE 60315296D1
Authority
DE
Germany
Prior art keywords
cpp
cell
present
relates
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60315296T
Other languages
English (en)
Other versions
DE60315296T2 (de
Inventor
Mattias Haellbrink
Margus Pooga
Madis Tallin Metsis
Priit Kogerman
Andreas Valkna
Anne Meikas
Maria Lindgren
Astrid Graeslund
Goeran Eriksson
Claes Goeran Oestensson
Metka Budihna
Matjaz Zorko
Anna Elmquist
Ursel Soomets
Pontus Lundberg
Peter Jaerver
Kuelliki Saar
Samir El-Andaloussi
Kalle Kilk
Uelo Langel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CEPEP II AB
Original Assignee
CEPEP II AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CEPEP II AB filed Critical CEPEP II AB
Application granted granted Critical
Publication of DE60315296D1 publication Critical patent/DE60315296D1/de
Publication of DE60315296T2 publication Critical patent/DE60315296T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0448—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil tropane or nortropane groups, e.g. cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
DE60315296T 2002-06-18 2003-06-18 Zell-selektives Abgabe System Expired - Lifetime DE60315296T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0201863A SE0201863D0 (en) 2002-06-18 2002-06-18 Cell penetrating peptides
SE0201863 2002-06-18
US39178802P 2002-06-25 2002-06-25
US391788P 2002-06-25
PCT/IB2003/003163 WO2003106491A2 (en) 2002-06-18 2003-06-18 Cell penetrating peptides

Publications (2)

Publication Number Publication Date
DE60315296D1 true DE60315296D1 (de) 2007-09-13
DE60315296T2 DE60315296T2 (de) 2008-04-17

Family

ID=29738564

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315296T Expired - Lifetime DE60315296T2 (de) 2002-06-18 2003-06-18 Zell-selektives Abgabe System

Country Status (9)

Country Link
US (1) US20080234183A1 (de)
EP (1) EP1516184B1 (de)
JP (1) JP4503435B2 (de)
AT (1) ATE368853T1 (de)
AU (1) AU2003253125A1 (de)
DE (1) DE60315296T2 (de)
HK (1) HK1078130A1 (de)
SE (1) SE0201863D0 (de)
WO (1) WO2003106491A2 (de)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
EP2348047A1 (de) * 2000-04-21 2011-07-27 New England Medical Center G-Protein gekoppelte Rezeptor (GPCR)- agonisten und -antagonisten sowie Verfahren zur GPCR-Aktivierung/-Inhibierung
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
EP1512696A1 (de) * 2003-08-14 2005-03-09 Diatos Aminsäuresequenz, die den Transfer von Substanzen von Interesse in das Innere von Zellen und/oder Zellkernen erleichtern
ES2330115T3 (es) * 2003-08-14 2009-12-04 Cellectis Composicion antibacteriana, mas particilarmente contra las bacterias gram-negativas, que comprende un peptido y un agente antibacteriano ventajosamente hidrofobo.
AU2004287884C1 (en) 2003-11-05 2012-11-29 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
MXPA06012605A (es) * 2004-05-04 2006-12-15 Nastech Pharm Co Composiciones y metodos para mejorar el suministro de acidos nucleicos en celulas y para modificar la expresion de genes objetivo en celulas.
WO2006049442A1 (en) * 2004-11-03 2006-05-11 Forhumantech. Co., Ltd. Pharmaceutical compositions for transdermal delivery
EP1814911A2 (de) * 2004-11-04 2007-08-08 New England Medical Center Hospitals, Inc. G-protein-gekoppelte rezeptor-agonisten und antagonisten sowie verwendungsverfahren
FR2877946B1 (fr) 2004-11-12 2011-02-11 Commissariat Energie Atomique Peptides derives de la maurocalcine utilisables comme vecteurs pour l'adressage intracellulaire de molecules d'interet
US7741275B2 (en) 2004-12-22 2010-06-22 Lipopeptide Ab Agents and use thereof
ES2399267T3 (es) 2005-01-18 2013-03-27 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Suministro selectivo de moléculas al interior de las células o marcación de células en zonas enfermas de tejidos usando un péptido transmembrana sensible a su entorno
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CN101351554B (zh) 2005-10-04 2016-05-18 索利金尼克斯公司 包括通过调节先天免疫治疗和预防感染在内的治疗和预防免疫相关疾病的新型肽
WO2007105565A1 (ja) * 2006-03-13 2007-09-20 Keio University インフルエンザ感染阻害ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ予防・治療剤
US8642559B2 (en) * 2006-10-13 2014-02-04 University Of Southern California C-terminal domain truncation of mGluR1α by calpain and uses thereof
PT2341142E (pt) 2006-12-28 2015-02-13 Int Inst Cancer Immunology Inc Péptido wt1 restringido a hla-a*1101 e composição farmacêutica compreendendo o mesmo
CA2676797C (en) * 2007-01-29 2014-04-22 Dae Woong Jo Novel macromolecule transduction domains and methods for identification and uses thereof
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
DE102007008596B4 (de) * 2007-02-15 2010-09-02 Friedrich-Schiller-Universität Jena Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung
EP3159352B1 (de) 2007-03-28 2023-08-02 President and Fellows of Harvard College Geheftete polypeptide
US9078927B2 (en) * 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
AU2008295509A1 (en) 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
WO2009041902A1 (en) * 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
TW200932260A (en) * 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides
EP2242503A4 (de) 2008-02-08 2012-04-25 Aileron Therapeutics Inc Therapeutische peptidomimetische macrocyclen
DE102009043743B4 (de) 2009-03-13 2016-10-13 Friedrich-Schiller-Universität Jena Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung
EP2090584A1 (de) 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identifikation eines neuartigen Zystein-reichen Peptids zur Zellenpenetration
CA2713872A1 (en) * 2008-02-21 2009-08-27 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
GB0804496D0 (en) 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
WO2009120993A2 (en) * 2008-03-28 2009-10-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Synthetic analogs of the juxtamembrane domain of igf1r and uses thereof
WO2009137689A2 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US20110250685A1 (en) * 2008-06-03 2011-10-13 Nash Huw M Compositions and methods for enhancing cellular transport of biomolecules
US8575305B2 (en) 2008-06-04 2013-11-05 Medical Research Council Cell penetrating peptides
EP3168231A1 (de) 2008-06-12 2017-05-17 Centre for Addiction and Mental Health Zusammensetzungen und verfahren zur modulierung der d1-d2-dopaminrezeptorinteraktion und -funktion
US20110218334A1 (en) * 2008-07-11 2011-09-08 Alnylam Pharmaceuticals, Inc. PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
CA2737921C (en) 2008-09-22 2019-01-15 Aileron Therapeutics, Inc. Methods for preparing purified alpha-helical peptidomimetic macrocycle compositions with low metal ppm levels
US20140248296A1 (en) * 2008-10-16 2014-09-04 Kathleen Cogan Farinas Sustained drug delivery system
US20110294738A1 (en) * 2008-11-04 2011-12-01 Yong Ren Pthr1 receptor compounds
WO2010053547A2 (en) * 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Cxcr5 receptor compounds
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
EP2641911A3 (de) * 2008-12-23 2014-01-01 Vivoscript, Inc. Zusammensetzungen und Verfahren zur Neuprogrammierung von Zellen ohne genetische Modifikation
CA2744088A1 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US8658762B2 (en) 2009-04-09 2014-02-25 Centre For Addiction And Mental Health Polypeptides that inhibit dopamine D2 receptor-DISC1 interaction and methods of use thereof
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
GB0910620D0 (en) 2009-06-19 2009-08-05 Immunovia Ab Agents and uses thereof
CA2766634A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
BR112012000867A2 (pt) 2009-07-13 2019-09-24 Harvard College "polipeptídeos bifuncional costurado e uso do mesmo"
WO2011038002A1 (en) * 2009-09-22 2011-03-31 Yale University Immunogenic epitopes as targets for universal cancer vaccines
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011072292A2 (en) * 2009-12-11 2011-06-16 Dicerna Pharmaceuticals, Inc. Phase changing formulations of rna and rna derivatives
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
WO2011139907A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
EP2566495B1 (de) 2010-05-03 2017-03-01 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-alpha-trna-synthetasen
AU2011248355B2 (en) 2010-05-03 2017-01-19 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
EP2566499B1 (de) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex
AU2011252990B2 (en) 2010-05-14 2017-04-20 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
JP6046607B2 (ja) 2010-05-27 2016-12-21 エータイアー ファーマ， インコーポレイテッド グルタミニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103118694B (zh) 2010-06-01 2016-08-03 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
US9540680B2 (en) * 2010-06-07 2017-01-10 The Trustees Of The University Of Pennsylvania Transcriptome in vivo analysis
WO2011157713A2 (en) 2010-06-14 2011-12-22 F. Hoffmann-La Roche Ag Cell-penetrating peptides and uses therof
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP2013534525A (ja) * 2010-06-23 2013-09-05 ヴィヴォスクリプト，インコーポレイテッド 心臓疾患の治療のために遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法
CA2804416C (en) 2010-07-12 2020-04-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
EP2611791A4 (de) 2010-08-12 2014-02-12 Univ New York Oligooxopiperazine sowie verfahren zu ihrer herstellung und verwendung
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP5753903B2 (ja) * 2010-08-24 2015-07-22 ロシュ グリクアート アーゲー 活性化可能な二重特異性抗体
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA2808539C (en) 2010-08-25 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9518105B2 (en) * 2010-12-08 2016-12-13 The Research Foundation For The State University Of New York Polypeptides derived from calcitonin receptors and methods of use
US20140056811A1 (en) 2010-12-27 2014-02-27 Compugen Ltd. New cell-penetrating peptides and uses thereof
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
WO2012139137A2 (en) 2011-04-08 2012-10-11 Tufts Medical Center, Inc. Pepducin design and use
CA2834577A1 (en) * 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
EP2715291A4 (de) 2011-05-31 2015-10-21 Airware Inc Rekalibrierung von ab-ndir-gassensoren
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
EP2537858A1 (de) 2011-06-20 2012-12-26 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Kleine effiziente zelleindringende Peptide aus dem Skorpiongift Maurocalcin
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US9302014B2 (en) 2011-08-30 2016-04-05 Medical Research Council Cell-penetrating peptides having a central hydrophobic domain
US9624284B2 (en) * 2011-09-13 2017-04-18 Immunotope, Inc. Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
CN104487450B (zh) 2011-11-24 2018-09-21 苏州宝时得电动工具有限公司 多肽序列设计及其在多肽介导的siRNA传递中的应用
CN102532565B (zh) * 2011-12-19 2013-08-28 上海交通大学 可降解亚胺类聚阳离子及其合成方法、纳米颗粒
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013123511A1 (en) 2012-02-16 2013-08-22 New York University Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
EP2864348A2 (de) 2012-06-26 2015-04-29 F. Hoffmann-La Roche AG Zellpenetrierende peptide und verfahren zur identifikation zellpenetrierende peptide
AU2013296218B2 (en) 2012-08-03 2019-07-18 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
EP2708235A1 (de) 2012-09-17 2014-03-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Peptidantagonisten des Vasopressin-2-Rezeptors
EP3872067A1 (de) 2012-09-26 2021-09-01 President And Fellows Of Harvard College Prolinderivate
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
AU2013347797A1 (en) * 2012-11-25 2015-07-02 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
ITMI20122263A1 (it) * 2012-12-28 2014-06-29 Azienda Ospedaliero Universitaria Di Parma Nuovi peptidi cationici ciclici ad attività antimicrobica
CA3085079A1 (en) 2013-03-13 2014-10-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
EP2784094A1 (de) 2013-03-28 2014-10-01 Commissariat A L'energie Atomique Et Aux Energies Alternatives Neue uranchelatisierende, vom EF-Hand-Calciumsbindungsmotiv abgeleitete Peptide zur Uran-Biodetektion und -Biodekontamination
EP2981555B1 (de) 2013-03-28 2020-04-15 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Neue uranchelatisierende, vom ef-hand-calciumsbindungsmotiv abgeleitete peptide zur uran-biodetektion und -biodekontamination
CN105492460A (zh) 2013-06-14 2016-04-13 哈佛大学的校长及成员们 稳定化多肽胰岛素受体调控剂
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US20160146786A1 (en) * 2013-06-26 2016-05-26 Phylogica Limited Method of monitoring cellular trafficking of peptides
KR20160023669A (ko) 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
EP2842566A1 (de) 2013-09-03 2015-03-04 Centre National De La Recherche Scientifique Verwendung von Arpin als neuer Hemmer des ARP2/3-Komplexes zur Diagnose und Behandlung von Krankheiten
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
JP6493216B2 (ja) * 2013-11-05 2019-04-03 味の素株式会社 ペプチドヒドラジド、ペプチドアミド及びペプチドチオエステルの製造方法
JP6865584B2 (ja) * 2013-12-23 2021-04-28 コヴァラブ 化合物の共有結合性コンジュゲーションのためのｍＴＧ基質
WO2015105957A1 (en) * 2014-01-08 2015-07-16 Shriners Hospitals For Children Pten antagonist peptides and methods of using the same
WO2015108955A2 (en) * 2014-01-15 2015-07-23 The Board Of Regents Of The University Of Texas System Targeting of pelp1 in cancer therapy
EP3791889B1 (de) 2014-01-17 2024-02-21 Cedars-Sinai Medical Center Auf den c-met rezeptor abzielende konstrukte und verwendungen davon
EP2905031A1 (de) 2014-02-10 2015-08-12 B Cell Design Neues, nicht-HIV-Impfstoff-Antigen aus der vaginalen Mikrobiota zur Induzierung einer mukosalen, neutralisierenden, schützenden Antikörperreaktion gegen eine HIV-Infektion
MX2016013025A (es) 2014-04-04 2017-04-27 Cedars Sinai Medical Center Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3.
CA2949535C (en) 2014-05-21 2023-09-12 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MX2017003819A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
PL3388075T3 (pl) 2015-03-27 2023-12-11 Immatics Biotechnologies Gmbh Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem różnych nowotworów
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
WO2017083618A1 (en) 2015-11-13 2017-05-18 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
WO2017087505A1 (en) * 2015-11-17 2017-05-26 The Regents Of The University Of Michigan Macromolecular structures and uses thereof
EP4039698A1 (de) 2016-03-15 2022-08-10 IDP Discovery Pharma, S.L. Peptide mit antikrebsaktivität
GB201607521D0 (en) * 2016-04-29 2016-06-15 Oncolmmunity As Method
EP3484482A4 (de) * 2016-07-15 2020-07-29 The Board of Regents of the University of Oklahoma Anti-arid3a-behandlungen für entzündliche erkrankungen
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
TWI781963B (zh) 2016-11-09 2022-11-01 俄亥俄州立創新基金會 含二硫化物細胞穿透肽及其製造與使用方法
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
IL293710B2 (en) 2016-12-07 2024-10-01 Molecular Templates Inc Shiga toxin A subunit activator polypeptides, Shiga toxin activator scaffolds and cell-targeting molecules for site-specific conjugation
EP3360891B1 (de) 2017-02-14 2022-03-30 Karlsruher Institut für Technologie Zellenpenetrierende peptide menschlichen ursprungs
EP3628047A1 (de) 2017-05-02 2020-04-01 Sanford Burnham Prebys Medical Discovery Institute Tumorassoziiertes monozyten-/makrophagenbindendes peptid und verfahren zur verwendung davon
KR102095284B1 (ko) * 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체
EP3654941A1 (de) 2017-07-17 2020-05-27 Keith Roizman Topische verabreichung von therapeutischen mitteln mit zellpenetrierenden peptiden zur verwendung zur behandlung von altersbedingter makuladegeneration und anderen augenerkrankungen
US20200223894A1 (en) * 2017-09-19 2020-07-16 Auckland Uniservices Limited Peptides for the treatment of conditions associated with adiponectin dysfunction
AU2018378201A1 (en) * 2017-12-04 2020-05-21 Heat Biologics, Inc. Production of cell-based vaccines
US20210363192A1 (en) * 2018-04-27 2021-11-25 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
WO2020010103A1 (en) * 2018-07-02 2020-01-09 Ohio State Innovation Foundation Polypeptide conjugates for intracellular delivery of nucleic acids
KR20210064254A (ko) * 2018-09-26 2021-06-02 가부시키가이샤 가네카 세포막 투과성 펩티드
JP2022528298A (ja) * 2018-12-07 2022-06-10 オックスフォード ユニバーシティ イノベーション リミテッド リンカー
CN118079011A (zh) 2019-02-01 2024-05-28 利兰斯坦福初级大学董事会 用于将核酸递送至肺部的分解性细胞穿透复合物
US20220119450A1 (en) * 2019-02-04 2022-04-21 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
US20220259273A1 (en) * 2019-03-05 2022-08-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating protein aggregation-associated diseases
KR20220034182A (ko) 2019-07-11 2022-03-17 시아먼 유니버시티 분자의 세포내 전달용 복합체
US20210038729A1 (en) * 2019-07-22 2021-02-11 Oneskin, Inc. Polypeptides having anti-senescent effects and uses thereof
AR119529A1 (es) * 2019-08-02 2021-12-22 Idp Discovery Pharma S L Péptidos reguladores de melanocitos
KR20220121867A (ko) 2019-12-31 2022-09-01 시아먼 유니버시티 분자의 세포 내 전달을 위한 다량체화 전달 시스템
EP3906935A1 (de) 2020-05-06 2021-11-10 Sorbonne Universite Peptide zur vorbeugung oder behandlung viraler infektionen
CN113943778A (zh) * 2020-07-17 2022-01-18 通用电气医疗集团股份有限公司 用于核酸检测的分子探针及其制备方法和用途
WO2022157548A1 (en) 2021-01-24 2022-07-28 Forrest Michael David Inhibitors of atp synthase - cosmetic and therapeutic uses
US20240182526A1 (en) * 2021-03-31 2024-06-06 University Of Southern California Compositions and methods for modulting inflammatory and degenerative disorder
JP2024513087A (ja) 2021-04-07 2024-03-21 アストラゼネカ・アクチエボラーグ 部位特異的改変のための組成物及び方法
CN115385987B (zh) * 2021-05-19 2024-08-02 中山大学 一种抗鱼类神经坏死病毒的穿膜肽及其应用
KR102504190B1 (ko) * 2021-06-03 2023-02-28 주식회사 레메디 화물분자 수송 도메인 rmmr1, 이의 변이체, 이를 포함하는 재조합 화물분자 및 이를 이용한 화물분자 수송 방법
CN114349846B (zh) * 2022-01-07 2023-12-15 天津市泌尿外科研究所 一种人精子膜蛋白or1d2特异性多肽与抗体的制备方法
WO2023181070A1 (en) * 2022-03-23 2023-09-28 Council Of Scientific & Industrial Research PEPTIDE TO TREAT α-SYNUCLEIN AMYLOID BASED DISORDERS
CN116444678B (zh) * 2022-10-18 2024-02-02 百葵锐(深圳)生物科技有限公司 一种具有真菌抗菌抑菌性能的新型多肽
WO2024119101A1 (en) 2022-12-01 2024-06-06 Yale University Stimuli-responsive traceless engineering platform for intracellular payload delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE251913T1 (de) * 1997-05-21 2003-11-15 Univ Leland Stanford Junior Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen
JP4465109B2 (ja) * 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
CA2354044A1 (en) * 1998-12-10 2000-06-15 Washington University Protein transduction system and methods of use thereof
WO2001097830A1 (en) * 2000-06-22 2001-12-27 Mount Sinai School Of Medicine Modification of mdm2 activity
FR2810985B1 (fr) * 2000-07-03 2004-12-24 Synt Em Peptides lineaires amphipathiques et les compositions les contenant
NZ524386A (en) * 2000-08-25 2005-10-28 Aventis Pharma Inc Membrane penetrating peptides and uses thereof
EP1581615B1 (de) * 2000-09-05 2010-04-28 Biosight Ltd Peptid-konjugierte antikrebs-prodrugs
FR2818981A1 (fr) * 2001-01-03 2002-07-05 Synt Em Peptides amphipathiques et leur utilisation pour le transfert de substances d'interet dans les cellules
AU2002240201A1 (en) * 2001-02-02 2002-08-19 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
WO2003064453A2 (de) * 2002-01-27 2003-08-07 Viromics Gmbh Trojanische inhibitoren, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
HK1078130A1 (en) 2006-03-03
US20080234183A1 (en) 2008-09-25
AU2003253125A8 (en) 2003-12-31
DE60315296T2 (de) 2008-04-17
JP4503435B2 (ja) 2010-07-14
AU2003253125A1 (en) 2003-12-31
WO2003106491A2 (en) 2003-12-24
WO2003106491A3 (en) 2004-12-23
EP1516184A2 (de) 2005-03-23
SE0201863D0 (en) 2002-06-18
ATE368853T1 (de) 2007-08-15
EP1516184B1 (de) 2007-08-01
JP2006514602A (ja) 2006-05-11

Similar Documents

Publication Publication Date Title
DE60315296D1 (de) Zell-selektives Abgabe System
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
GEP20125594B (en) Sclerostin binding agents
HUP0300246A2 (en) Delivery system
IL178515A0 (en) Oligopeptides for reducing elevated blood urea concentration
DE60236206D1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
HK1089190A1 (en) Rasgap derived peptide for selectively killing cancer cells
DE69938935D1 (de) Zyklische conotoxin-peptide
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
EP1801232A4 (de) Verfahren zum screening eines transmembranenzymhemmstoffs
TW200508249A (en) Antibodies for the cancer specific antigen
EA200700990A1 (ru) Новые пептиды, которые связывают рецептор эритропоэтина
ATE360644T1 (de) Vegf-peptide und deren verwendung
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
WO2010133806A3 (fr) Peptides marques et leur utilisation pour le dosage d'irap circulant
WO2006113429A3 (en) Viral inhibitors
SI1668027T1 (sl) Ciklični peptidi delujoči kot antagonisti urotenzina ii
DE60327467D1 (de) Mss4 als antifungisches zielmolekül
SE0401166D0 (sv) Method for protein protection

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: HAELLBRINK, MATTIAS, S-113 28 STOCKHOLM, SE

Inventor name: POOGA, MARGUS, E-51010 TARTU, EE

Inventor name: METSIS, MADIS TALLIN UNIVE, 12618 TALLINN, EE

Inventor name: KOGERMAN, PRIIT, E-79601 TABASALU, EE

Inventor name: VALKNA, ANDREAS, VIIMSI, EE

Inventor name: MEIKAS, ANNE, SAKU ESTONIA, EE

Inventor name: LINDGREN, MARIA, S-113 28 STOCKHOLM, SE

Inventor name: GRAESLUND, ASTRID, S-191 44 SOLLENTUNA, SE

Inventor name: ERIKSSON, GOERAN, S-116 43 STOCKHOLM, SE

Inventor name: OESTENSSON, CLAES GOERAN, S-171 64 SOLNA, SE

Inventor name: BUDIHNA, METKA, 1210 LJUBLJANA-SENTVID, SI

Inventor name: ZORKO, MATJAZ, SKOFLJICA, SI

Inventor name: ELMQUIST, ANNA, S-761 71 NORRTAELJE, SE

Inventor name: SOOMETS, URSEL, TARTU, EE

Inventor name: LUNDBERG, PONTUS, S-169 72 SOLNA, SE

Inventor name: JAERVER, PETER, S-116 67 STOCKHOLM, SE

Inventor name: SAAR, KUELLIKI, S-113 53 STOCKHOLM, SE

Inventor name: EL-ANDALOUSSI, SAMIR, S-104 05 STOCKHOLM, SE

Inventor name: KILK, KALLE, S-182 38 DANDERYD, SE

Inventor name: LANGEL, UELO, S-124 32 BANDHAGEN, SE

8364 No opposition during term of opposition